Wall Street consensus, price target range, and equity research thesis
Wall Street currently rates AZN buy with a 12-month price target of $187 (+0.1% upside). The sections below cover the bull case, key risks, and latest earnings context for AstraZeneca PLC.
Analyst ratings update weekly. Get AZN's next verdict in your inbox.
Free. No account needed. Unsubscribe any time.
Analyst Research Summary
A structured look at the bull case, the risks, and the most recent earnings execution for AZN.
AZN beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.
What keeps the long thesis intact
Wall Street rates AZN buy, giving the bull case institutional backing from 41 analysts.
What can break the setup quickly
Watch whether new negative commentary on AZN points to these structural risks or is simply reacting to short-term price moves.
Last Quarter
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Stock snapshot, live price chart, key ratios, and company profile.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AZN stock.
AZN appears fairly valued near today's $186.43 — the consensus rating is "Buy" with a $187 target (+0.1%). This is informational only — verify the data and consider your own risk tolerance before deciding.
Timing depends on your horizon, but the data signals are: consensus rating "Buy" with +0.1% upside to the $187 target.
AZN's consensus 12-month price target is $187, set by 41 Wall Street analysts. The bull case high is $216 and the bear case low is $158. From the current price of $186.43, this implies +0.1% upside.
AZN appears fairly valued — the $187 consensus target is roughly in line with today's $186.43 (+0.1%). It trades at a forward P/E of 18.2x. Targets range from $158 (bear) to $216 (bull), reflecting different assumptions about growth and margins.
AZN reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $187 target. Consider position sizing rather than going all-in pre-print.
Of 41 analysts covering AstraZeneca PLC (AZN): 1 Strong Buy, 19 Buy, 15 Hold, 6 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $187 (range $158–$216). Bullish analysts outnumber bearish by more than 2-to-1.
6 of the 41 analysts covering AZN rate it Sell or Strong Sell. Common concerns include valuation stretch, slowing growth, and sector-specific headwinds — see the Bull vs. Risk cards above for the specific theses on AstraZeneca PLC.
Financial Data & Software Notice: VCP Scanner is an educational financial research database and stock screening software platform. VCP Scanner does not generate, recommend, or package trade decisions, buy/sell signals, or personalized investment advice. Consensus ratings and price targets reflect aggregated third-party Wall Street analyst research from public SEC filings. See our Terms of Service and Privacy Policy.